In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 4, 2000, Pages 1102-1107

  Milatovic, Dana ^a,b   Schmitz, Franz Josef ^a   Brisse, Sylvain ^a   Verhoef, Jan ^a   Fluit, Ad C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; GATIFLOXACIN; MOXIFLOXACIN; SITAFLOXACIN; TROVAFLOXACIN;

ACINETOBACTER; ANTIBIOTIC SENSITIVITY; ARTICLE; CITROBACTER FREUNDII; ENTEROBACTER; ENTEROCOCCUS; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NEISSERIA; NONHUMAN; PRIORITY JOURNAL; PROTEUS; PROVIDENCIA; PSEUDOMONAS AERUGINOSA; SALMONELLA; SERRATIA; SHIGELLA; STAPHYLOCOCCUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS; YERSINIA ENTEROCOLITICA;

ANTI-INFECTIVE AGENTS; BACTERIA; BACTERIAL INFECTIONS; COLONY COUNT, MICROBIAL; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; HUMANS;

EID: 0034102922     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.4.1102-1107.2000     Document Type: Article

References (22)

1. Bauernfeind, A. 1997. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J. Antimicrob. Chemother. 40:639-651.
2. Cohen, M. A., M. D. Huband, J. W. Gage, S. L. Yoder, G. E. Roland, and S. J. Gracheck. 1997. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin. J. Antimicrob. Chemother. 40:205-211.
3. Cormican, M. G., S. A. Marshall, and R. N. Jones. 1995. Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin). Diagn. Microbiol. Infect. Dis. 21:51-54.
4. Fuchs, P. C., A. L. Barry, and S. D. Brown. 1998. In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers. Antimicrob. Agents Chemother. 42:1274-1277.
5. Hecht, D. W., and H. M. Wexler. 1996. In vitro susceptibility of anaerobes to quinolones in the United States. Clin. Infect. Dis. 23(Suppl. 1):S2-S8.
6. Jones, R. N., M. S. Barrett, and D. J. Biedenbach. 1994. Interpretive criteria for susceptibility tests with DU-6859a and FK-037 tested against Haemophilus influenzae and Neisseria gonorrhoeae. Diagn. Microbiol. Infect. Dis. 19:93-99.
7. Jones, R. N., D. M. Johnson, D. J. Biedenbach, and S. A. Marshall. 1995. Activity of two novel fluoroquinolones (DU-6859a and DV-7751a) tested against glycopeptide-resistant enterococcal isolates. Diagn. Microbiol. Infect. Dis. 23:123-127.
8. Kato, N., H. Kato, K. Tanaka-Bando, K. Watanabe, and K. Ueno. 1996. Comparison of in vitro activities of DU-6859a and other fluoroquinolones against Japanese isolates of anaerobic bacteria. Clin. Infect. Dis. 23(Suppl. 1):S31-S35.
9. Kawada, Y. 1999. Sitafloxacin (DU-6859a) in the treatment of genitourinary tract infections. J. Antimicrob. Chemother. 44(Suppl. A):142.
10. Kobayashi, H. 1999. The clinical efficacy of sitafloxacin (DU-6859a) in respiratory tract infection. J. Antimicrob. Chemother. 44(Suppl. A):130.
11. Korten, V., I. Erdem, and B. E. Murray. 1996. Bactericidal activity of the fluoroquinolone DU-6859a alone and in combination with other antimicrobial agents against multiresistant enterococci. Diagn. Microbiol. Infect. Dis. 26:79-85.
12. Marshall, S. A., and R. N. Jones. 1993. In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone. Antimicrob. Agents Chemother. 37:2747-2753.
13. Nakane, T., S. Iyobe, K. Sato, and S. Mitsuhashi. 1995. In vitro antibacterial activity of DU-6859a, a new fluoroquinolone. Antimicrob. Agents Chemother. 39:2822-2826.
14. Nakashima, M., T. Uematsu, K. Kosuge, K. Umemura, H. Hakusui, and M. Tanaka. 1995. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob. Agents Chemother. 39:170-174.
15. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
16. National Committee for Clinical Laboratory Standards. 1997. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard M11-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
17. Nord, C. E. 1996. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria. Clin. Infect. Dis. 23(Suppl. 1):S15-S18.
18. Summanen, P., E. J. Baron, D. Citron, C. Strong, H. M. Wexler, and S. M. Finegold. 1993. Wadsworth anaerobic bacteriology manual, 5th ed. Star Publishing Company, Belmont, Calif.
19. Takifuji, K., H. Tanimura, Y. Nagai, and S. Iwakura. 1999. Clinical effects of sitafloxacin (DU-6859a) on surgical infection and pharmacokinetic evaluation. J. Antimicrob. Chemother. 44:146.
20. Visalli, M. A., S. Bajaksouzian, M. R. Jacobs, and P. C. Appelbaum. 1997. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods. Antimicrob. Agents Chemother. 41:1475-1481.
21. Visalli, M. A., M. R. Jacobs, and P. C. Appelbaum. 1996. MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. 40:362-366.
22. Wexler, H. M., E. Molitoris, D. Reeves, and S. M. Finegold. 1994. In vitro activity of DU-6859a against anaerobic bacteria. Antimicrob. Agents Chemother. 38:2504-2509.